Fibroblasts Contribute To Melanoma Tumor Growth

	Tweet

Fibroblasts, cells that play a role in the structural framework of tissues, play an apparent role in melanoma tumor growth. Fibroblasts also contribute to melanoma drug resistance and may also facilitate the “flare” response when a tumor’s metabolism is enhanced following a patient being removed from a targeted therapy, said researchers at Moffitt Cancer Center in Tampa, Fla.

Alexander R. Anderson, Ph.D., co-director of Integrative Mathematical Oncology at Moffitt, and Moffitt Comprehensive Melanoma Research Center member Keiran S. Smalley, Ph.D., along with colleagues from the Wistar Institute in Philadelphia, investigated the role of fibroblasts in melanoma progression and published their findings in a recent issue of Molecular Pharmaceutics.

“A role for fibroblasts in cancer progression has long been suspected,” explained Anderson, who works with mathematical models of cancer to investigate tumor cell- microenvironment interactions. “In this study, we used an integrated mathematical and experimental approach to investigate whether melanoma cells recruit, activate and stimulate fibroblasts to deposit certain proteins known to be pro-survival for melanoma cells.”

Fibroblasts are the most common of connective tissues, and they function to synthesize the “extra cellular matrix” of cells and collagen, the structural framework – also called “stroma” – for tissues.

The researchers knew that fibroblasts were drawn to cancer cells and that they became activated by cancer cells. They also knew that different cancer cell lines have varying capabilities for recruiting and stimulating fibroblasts. An expectation has been that aggressive cancers stimulate fibroblasts more than do less aggressive cancers.

When they investigated the relationship between fibroblasts and tumors using mathematical models, the research team came up with some unexpected findings.

Anderson and Smalley expected the fibroblast-derived “extra cellular matrix” that supports the tumor structure to have “direct effects on tumor behavior.” However, once they ran their theoretical models they came up with a number of unexpected conclusions with potentially far-reaching implications about drug resistance and tumor growth.

“Our finding that the fibroblast population might facilitate the “flare response” – a period during which a tumor has enhanced metabolism and increases it progression trajectory after patients are removed from targeted therapy – was a surprise,” said Smalley, whose research aims at developing new therapies for melanoma and getting them into clinical practice.

The researchers knew that a targeted therapy would kill only the tumor population, not the fibroblasts in the tumor structure. However, the finding that fibroblasts contribute to melanoma drug resistance was unexpected.

“Targeted therapies may actually hasten tumor progression when they are stopped due to resistance to the targeted drug,” said Smalley. “We found in our models that fibroblasts appear to facilitate the flare response after targeted therapy ends.”

Their conclusions about the relationship between fibroblasts and cancer tumors were not predicted or expected, but revealed though the use of mathematical models.

“If these conclusions are confirmed experimentally, we may gain important new insights into how drug resistance can be managed clinically,” concluded Anderson.

###
About Moffitt Cancer Center

Located in Tampa, Florida, Moffitt Cancer Center is an NCI Comprehensive Cancer Center – a designation that recognizes Moffitt’s excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 14 affiliates in Florida, one in Georgia, one in Pennsylvania and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of “America’s Best Hospitals” for cancer. Moffitt marks a very important anniversary in 2011 – 25 years committed to one mission: to contribute to the prevention and cure of cancer.

Media release by Florida Science Communications

RELATED STORIES:
Childhood cancer survivors at increased risk of sarcoma   Unhealthy Behaviors More Prevalent in Survivors of Multiple Cancers, Study Shows   Yttrium-90 to control hepatocarcinoma   Cervical cancer test not recommended enough: study   Ark says cancer therapy potent, cuts side-effects   Reovirus could be used to treat many forms of advanced cancer   Scientists identify a new gene that causes the spread of cancer   Compound that blocks sugar pathway slows cancer cell growth   A tonic against non-Hodgkin lymphoma?   Mount Sinai researchers discover possible new target for sarcoma treatment and prevention   Novel Anti-Cancer Mechanism Found in Long-Lived Rodents   Small Gift Makes Big Impact in Lives of Cancer Patients   Black raspberries slow cancer by altering hundreds of genes   Access to cancer care unequal across Europe   Personality not linked to cancer risk or prognosis   Yeast unravels effects of chemotherapy drugs   Men with BRCA2 gene mutation have higher cancer risk   Botox Could Help Target Resistant Tumors for Treatment   How Infection and Inflammation Can Lead to Cancer   Cancer Drug Aids an Anti-Cancer Virus   Regimen May Hike Survival in Advanced Cancer   Researchers Find Better Method to Help Mothers Cope With Child’s Cancer and Related Stress

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]